Coombe confirmed as chief financial officer at Glaxo SmithKline

Coombe, who also heads to 100 Group of Finance Directors, will take up his post upon completion of the £114bn merger.

The only executive casualties from SmithKline’s board were announced as chief executive Jan Leschly, who is retiring six months early, and finance director Andrew Bonfield who is stepping down.

The merger will create a company with an estimated 7.3% share of the global pharmaceutical market. The company will have a research and development budget of around £2.4bn and 40,000 employees.

Coombe gets top job

Glaxo FD Coombe bags top job at new £114bn drugs giant Glaxo SmithKline

Related reading